3 to 4 years of mergers and acquisitions of 20 to 30 pharmaceutical companies

    Since 2013, Guangzhou Pharmaceuticals and Baiyunshan A, a subsidiary of Cantonese Pharmaceutical Group, successfully completed major asset reorganizations，This year as the beginning of the rise of Xinguang Pharmaceutical，Da South Medicine、Big Health、Big Commercial & RDQUO; Under the structure of the three major business groups，Dannan Pharmaceuticals took the lead in the year of the horse。

    Guangyao Group announced recently，It will be before the new version of GMP certification is about to expire，M & A 20-30 pharmaceutical manufacturing companies with good market potential and product advantages。

    & ldquo; Gold & RDQUO;

    Data display，As of December 31, 2013，A total of 1319 nationwide sterile drug manufacturers，Enterprises that have passed the new Stake Sports Bettingstake sports betting appversion of GMP ("Regulations for the Management of Drug Production Quality") account for 60.3%，There are still nearly 40 % of sterile drug manufacturers who have not passed GMP certification，2014 has fallen into a state of suspension。

    In addition，CFDA previously released the "Notice on the Relevant Matters of Medicine Technology Transfer in the process of implementing new revised drug production quality management specifications"，Allows the new version of GMP -certified enterprise to transfer production lines to the related product approval article。With the state's strictest control of the approval of drugs for drugs，Pharmaceutical approval from research and development、The cost and cost of the final approval time is very high，Therefore, the drug approval has not accidentally become the focus of the industry's attention。

    There have been rumors in the industry，The factory building left by companies that cannot pass GMP certification、Approval of high -quality land resources and drugs，It will become an important target for mergers and acquisitions of some large pharmaceutical companies。

    Director Wang Wenchu, Director of the Danan Pharmaceutical section of Guangyao Group，Opportunities for the new version of GMP authentication，M & A nationwide has development potential、Regional advantage、Policy advantage、Products or pharmaceutical manufacturing enterprises with resource advantages，Accelerate the development of the Danan Pharmaceutical Plate。

    According to an introduction，This year's mergers and acquisitions of the Danan Pharmaceutical sector of Guangyao Group will stake sports betting appstake betting appconcentrate on the development of approval and purchase of industrial enterprises。The purchase of the approval，It is mainly based on the varieties that are no longer renovated in the new version of GMP，The main goal will be based on injection and biopharmaceuticals in the near future; aspect of corporate mergers and acquisitions，A dominant enterprise that will be concentrated in mergers and acquisitions with the company's product structure。Current，Guangyao has set up a special group and merger and acquisition expert consulting committee，Specialized to carry out mergers and acquisitions，Accelerate the progress of mergers and acquisitions。

    Introduction of Wang Wenchu，The most important thing in M ​​& A is the excellent product approval、High -quality land and complementary production lines，Then consider the price and risk control。& ldquo; The acquisition will be based on the company as the main body，wide open information source，Collect relevant mergers and acquisitions information and resources，Plan for mergers and acquisitions of 20-30 pharmaceutical companies for the next 3 to 4 years。& rdquo;

    Discussion is in full swing

    It is reported，Guangyao Group's sales revenue last year reached 54.5 billion yuan，Compared with 27 billion yuan in 2010，Top over。& ldquo; We want to use the next 3 to 4 years，Strive to realize the double sales revenue，Make Xinguang Pharmaceutical among & lsquo; 100 billion clubs & rsquo;。& rdquo; Wang Wenchu ​​said。

    Based on this，The demand for leapfrog development in Guangyao is very urgent。Under the goal of double the sales revenue of Guangzhou stake betting appMy stake betting appPharmaceutical，Dannan medicine must undoubtedly increase the significant increase in income，In addition to the rapid development of itself，It also needs to be accelerated through capital integration and mergers and acquisitions。

    Facts，There is a large industry advantage in corporate mergers and acquisitions。Wang Wenchu ​​said，Many companies value Guangyao Group，First is a strong brand，Followed by the national sales network，Also involved in multiple categories in drug management。& ldquo; For Guangyao，The type suitable for mergers and acquisitions is more diversified，Preliminary disclosure of some news about the mergers and acquisitions of the pharmaceutical industry，From the market response，Many companies still hope to negotiate with Guangyao。& rdquo;

    Another disclosure，For a variety of different acquisition types & mdash; & mdash;，The transaction method is also different，Approval of the acquisition will be more cash，And the acquisition of enterprises is more through the holding or shares。

    In addition，Wang Wenchu ​​thinks，More Chinese pharmaceutical industry enterprises，But the average scale is not large，So the increase has always been the major direction of the development of the industry，Government departments also hope to further promote the development of the pharmaceutical industry to high concentration。& ldquo; Guang Pharmaceutical as a leading enterprise in China's pharmaceutical industry，It is definitely necessary to follow this industry trend to take a positive attitude。& rdquo;

    It is understood，At present, stake sports betting appStake Sports Bettingmore than 10 companies that have begun to negotiate with Guangyao's acquisition business，But detailed information about these companies，Guang Pharmaceutical is said to be temporarily unable to disclose，and will announce separately after the merger is successful。